News on January 10, according to the "Science and Technology Daily" report,Professor Huang Bo, Professor Qin Chuan of the Institute of Medical Laboratory Animals of the Chinese Academy of Medical Sciences and other research teams have developed a new strategy for treating the new crown virus infection.This method uses engineered cellular microparticles injected into the body to bind to the new crown virus, which can help the immune system clear the virus and suppress the inflammatory response.
The results of this research took 10 months to develop and have been published online in the academic journal "Cell and Molecular Immunology".The researchers said the cellular microparticles are rich in oxidized cholesterol and angiotensin-converting enzyme 2 (ACE2). When ACE2 is combined with the new crown virus, it can assist alveolar macrophages to swallow more of the new crown virus.
IT House learned that macrophages play an important role in the human body's free system, settling in large quantities in the fluid on the surface of the human alveoli. The cells can engulf particles such as microbes and viruses, helping to keep the alveoli clean.
Previous research by Bo's team has shown that the acidicity of the small cyst cavity in M1 macrophages helps the new coronavirus RNA break through the limits, enter the plasma, and initiate the replication program. The alkaline small cyst cavity in M2 macrophages can inhibit the isolation of new coronavirus RNA from the body, and can move the virus to the intracellular lysosome for explanation.
Based on this principle, the R&D team engineered a microparticle with an average diameter of 100 nanometers to oxidize cholesterol and ACE2, which, when combined with the new crown virus, could help M2 macrophages devour the virus.
This method can not only help treat the new crown virus infection, so that the virus load is reduced, but also found in mouse experiments, the method can also inhibit the inflammatory response and reduce the discomfort of patients.
Huang Bo said that as a new type of biological carrier, microparticles have been applied to clinical practice and have high safety. It combines the new crown virus, so that its targeted delivery macrophages are degraded, and inhibits the macrophage inflammatory response, which is expected to become a new strategy for the treatment of new crown.